Search NLS News

The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark, it states. “Scandinavian CRO is a great addition to our Labquality family completing our CRO business platform. Now, we are a full service CRO company, and we can continue […]

Genovis has announced the successful divestment of its antibody business to Leinco Technologies, a developer of antibodies for research and diagnostics. The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business, it states. The antibody business, while valuable, was deemed non-core to the company’s long-term growth […]

“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila. According to Mattila, Medaffcon can assist pharmaceutical companies in their research […]

Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy […]

It is the first case caused by clade I to be diagnosed outside the African continent, reports the Public Health Agency of Sweden. “In this case a person has been infected during a stay in the part of Africa where there is a major outbreak of mpox clade I. The person in Sweden who has […]

Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction of tumor size, 51 percent complete clearance rate of basal cell carcinomas (total removal), and 71 percent average reduction in tumor size of patients with […]

Ilya Pharma has closed a EUR 5 million funding round with mainly existing shareholders including the EIC Fund participating, but also welcoming six new shareholders. The funds are used to advance the company’s portfolio of three first-in-class immunotherapies for skin, gastro and lung indications to the next value adding milestones and facilitate more commercial and […]

Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as well as the key secondary endpoints of HiSCR90 and HiSCR100. “We are delighted that the Phase 3 HS trial of izokibep was successful, again confirming […]

Margrethe Sørgaard joins the company’s cross-functional R&D team following Calluna’s launch, to oversee the strategic development of the company’s clinical programs in line with regulatory guidelines and safety requirements. With over 25 years’ experience from different leading positions in clinical development and operation, medical affairs, and drug safety/pharmacovigilance, she will play a pivotal role in […]

Getting back to work after a long and relaxing holiday can be quite hard, here is some advice to make things easier and make your return less stressful. 1. Plan your return Most people focus on getting organized for departure, perhaps maximizing their time away and then comes home just the day before work begins. […]